Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Immuneering (NASDAQ:IMRX) is anticipated to post its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect Immuneering to post earnings of ($0.30) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 4, 2026 at 4:00 PM ET.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. On average, analysts expect Immuneering to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immuneering Price Performance

Immuneering stock opened at $6.04 on Monday. The company has a market cap of $390.79 million, a PE ratio of -4.38 and a beta of 0.43. The company has a fifty day moving average price of $5.29 and a two-hundred day moving average price of $5.75. Immuneering has a 12 month low of $1.10 and a 12 month high of $10.08.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a report on Monday, March 9th. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a report on Sunday, April 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently added to or reduced their stakes in the stock. EntryPoint Capital LLC bought a new stake in Immuneering in the fourth quarter valued at $206,000. Great Valley Advisor Group Inc. bought a new stake in Immuneering in the fourth quarter valued at $125,000. LPL Financial LLC lifted its stake in Immuneering by 30.0% in the fourth quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock valued at $192,000 after buying an additional 6,725 shares during the last quarter. Bank of America Corp DE lifted its stake in Immuneering by 53.6% in the third quarter. Bank of America Corp DE now owns 43,754 shares of the company’s stock valued at $306,000 after buying an additional 15,262 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Immuneering in the third quarter valued at $98,000. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.